The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include ...

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

California's first insulin pens will be for sale two years after the governor’s promised delivery date in 2024.

The FDA has accepted for review the sBLA for Afrezza (insulin human) inhalation powder in children and adolescents with type 1 or 2 diabetes.

Biocon Biologics recently announced that it would manufacture and supply insulin glargine pens to Civica under a multi-year ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

Adolescents and young adults with preexisting autoimmune disease are more likely to develop type 1 diabetes than those ...

Biosimilars saved Italy €3.1 billion in drug spending over a decade as uptake reached 80% of biologic use, according to the ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Gov. Gavin Newsom says California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to sell state-branded generic drugs at ...

Many people with diabetes prefer an insulin pump to insulin injections. Here's how to know if it's right for you.

With Deepavali just around the corner, aren’t we all buzzing with excitement? Homes twinkling with diyas, family gatherings, and that irresistible aroma of mith ...